
AbCelex Technologies is a privately-owned Canadian biotechnology company that has developed a proprietary camelid antibody platform and has engineered and tested an orally available class of antibodies in two infectious disease programs with proof of concept studies completed. AbCelex has demonstrated successful expression of more than 50 diverse protein target antigens, generated more than 10 large functional libraries of immune and naïve origin. Our platform enables to rationally design and optimise discovery and therapeutic candidates with extended half-live, increased proteolytic…
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.